[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cerebrovascular-event\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cerebrovascular-event":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,78,102],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100640711","prospective-italian-validation-of-sms-in-patients-with-suspected-acute-stroke-100640711",false,"NCT07601659","Prospective Italian Validation of SMS in Patients With Suspected Acute Stroke","Prospective Italian Multicenter Study for the Validation of the Stroke Mimics Score (SMS) in Patients With Suspected Acute Stroke","PIVA-SMS","Inclusion Criteria:\n\n* Age ≥ 18 years at the time of presentation to the Emergency Department.\n* Presentation to the Emergency Department with a clinical suspicion of acute stroke, identified at nursing triage and\u002For through activation of the stroke pathway.\n* Presentation to the Emergency Department during the 6-month prospective enrollment period.\n* Feasibility of real-time collection of the data required to calculate the Stroke Mimics Score (SMS), including:\n\nage, systolic blood pressure, presence\u002Fabsence of seizure at onset, presence\u002Fabsence of headache at onset, presence\u002Fabsence of confusion at onset, presence\u002Fabsence of syncope at onset, presence\u002Fabsence of isolated sensory deficit, presence\u002Fabsence of motor deficit, history of coronary artery disease, history of prior stroke or transient ischemic attack (TIA).\n\n* Availability of a final hospital discharge diagnosis at the end of hospitalization or Emergency Department observation.\n* Signed informed consent from the patient or caregiver. If the patient is unconscious upon arrival at the Emergency Department, deferred consent will be applied.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years.\n* Inability to fully collect the data required to calculate the Stroke Mimics Score (SMS).\n* Absence of a clearly defined final hospital discharge diagnosis.\n* Voluntary discharge, transfer, or death before completion of the diagnostic workup, in the absence of a reliable diagnosis.\n* Repeated Emergency Department visits for the same clinical event (only the first visit will be considered).","ALL","18 Years",{"count":20,"type":21},1000,"ESTIMATED","OBSERVATIONAL","The overall objective of the study is to prospectively validate the diagnostic accuracy of the Stroke Mimics Score (SMS). This score is calculated using information collected at the time of the patient's arrival in the Emergency Department (triage) and may assist clinicians in distinguishing between:\n\n1. cerebrovascular events (ischemic stroke, intracerebral hemorrhage, and transient ischemic attack \\[TIA\\]),\n2. stroke mimics (i.e., conditions that present with stroke-like symptoms but without actual infarction of brain tissue).\n\nIn addition, the study aims to compare its results with other existing tools and to evaluate its performance across different patient groups.\n\nSpecifically, the present research seeks to generate data on the reliability of the SMS tool in providing an accurate diagnosis.",[25,26,27,28,29],"Cerebrovascular Event","Acute Ischemic Stroke","Intracerebral Hemorrhage","TIA (Transient Ischemic Attack)","Stroke","NOT_YET_RECRUITING","2026-05-15",{"date":33,"type":34},"2026-05-22","ACTUAL",{"date":36,"type":21},"2026-06-01",{"date":38,"type":21},"2027-06-01",{"name":40,"class":41},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":63,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100539831","phase-4-atorvastatin-pretreatment-in-cerebrovascular-events-apices-after-flow-diverter-implantation-100539831","NCT06308952","Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation","Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation: Protocol of a Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial","Inclusion criteria:\n\n1. Aged 18 to 75 years old, male or non-pregnant female;\n2. UIA diagnosed by CTA, MRA, or DSA;\n3. Maximal aneurysmal diameter between 3 and 25mm;\n4. Understands the nature of the procedure and provision of written informed consent;\n5. Indications for FD implantation with or without adjunctive coiling;\n6. Is willing to return to the investigational site for follow-up according to our protocol.\n\nExclusion criteria:\n\nPatients will be excluded if they meet any of the following criteria:\n\n1. Contraindications to atorvastatin treatment or known allergy to atorvastatin;\n2. Pregnancy or lactation;\n3. Presence of other vascular lesions (coronary artery disease, abdominal aortic aneurysm, intracranial atherosclerotic stenosis, arteriovenous malformation, dural arteriovenous fistula, Moyamoya disease, etc.);\n4. Prolonged statin therapy (≥30 days) or prior indications for atorvastatin therapy according to the Chinese guidelines for lipid management (2023) 21;\n5. Ruptured aneurysms or target aneurysm received previous operative or endovascular treatment;\n6. Patient currently using drugs that interact with atorvastatin metabolism (including transporter inhibitors, cyclosporine, protease inhibitors, other lipid-lowering medications (such as fibrates, ezetimibe, pcsk9 inhibitor, etc.), antacids, erythromycin, cytochrome P450 enzyme, colchicine, etc.);\n7. Patients diagnosed with multiple intracranial aneurysms who require treatment for two or more intracranial aneurysms within a one-year period;\n8. The target aneurysm is non-saccular (dissecting, fusiform, pseudo, infectious, etc.)\n9. Other situations that the researcher deems unsuitable for inclusion in the study (inability to receive anti-platelet or anticoagulant medication; allergy or contraindication for the use of FD alloy, history of life-threatening allergy to contrast dye, ect).\n10. Patient was determined that intravenous general anesthesia or general anesthesia with tracheal intubation could not be tolerated.\n11. Unwilling to be followed up or likely to have poor treatment compliance at initial screening;\n12. Life expectancy less than 3 years;\n13. Severe neurological deficit that renders the patient unable to live independently (modified Rankin score ≥4);\n14. Enrollment in another trial.\n\nWithdrawal criteria\n\nIn this trial, participants who have provided written informed consent but are unable to complete the entire study for any reason will be withdrawn. These circumstances include the following:\n\n1. The participants voluntarily quit the trial for various reasons;\n2. Occurrence of serious adverse events (SAEs). The study may be terminated by the participants, principal investigators, ethics committee, sponsor, or regulatory authorities based on ethical considerations;\n3. Early termination of the process based on the investigator's judgment in order to prevent development of severe complications;\n4. Significant deviation in implementation, or the subject failed to comply with the scheduled protocol;\n5. Miss the follow-up due to changes in working\u002Fliving places, or fortuitous accident (traffic accident, bone fracture, accidental death, ect.). Thus, close follow-up should be conducted to determine their relationship with the usage of FD and experimental drug;\n6. Flawed or absence of informed consents.","75 Years",{"count":51,"type":21},354,"INTERVENTIONAL",[54],"PHASE4","APICES trial is an investigator-initiated, multicenter, multicenter, randomized, double-blind, placebo-controlled clinical trial that plans to enroll 396 patients with a 1-year follow-up, including a neurovascular imaging examination \\[digital subtraction angiography (DSA), CT angiography (CTA) or magnetic resonance angiography (MRA)\\] at 6 months after index treatment. It was designed in compliance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. The study was approved by the Ethics Committee of Zhujiang Hospital of South Medical University (2024-KY-032-02) and registered at ClinicalTrials.gov (NCT06308952). The participants will be recruited from twelve advanced stroke centers in China.",[25,57,58,59,60,61,62],"Stent Stenosis","Ischemic Stroke","Hemorrhagic Stroke","Stent Thrombosis","Death, Brain","Endothelial Dysfunction",[64,65,66,29],"Atorvastatin","Intracranial aneurysm","Flow-diverter devices","RECRUITING","2026-02-27",{"date":70,"type":34},"2026-03-03",{"date":72,"type":34},"2024-07-30",{"date":74,"type":21},"2027-12-31",{"name":76,"class":41},"Duan Chuanzhi",1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":52,"phases":87,"briefSummary":88,"conditions":89,"keywords":93,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":77},"100620140","phase-4-efficacy-and-safety-of-methylprednisolone-after-flow-diverter-stent-implantation-in-unruptured-intracranial-aneurysms-100620140","NCT07353749","Efficacy and Safety of Methylprednisolone After Flow-Diverter Stent Implantation in Unruptured Intracranial Aneurysms","Efficacy and Safety of Methylprednisolone in Preventing Adverse Cerebrovascular Events After Flow-Diverter Stent Implantation in Patients With Unruptured Intracranial Aneurysms: A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Trial","Inclusion Criteria:\n\n* （1）Aged ≥ 18 years; （2）Diagnosed with intracranial aneurysm (IA) via CTA, MRA, or DSA;\n\n  （3）IA size ranging from 3 to 25 mm;\n\n  （4）The patient and\u002For their authorized representative can understand the study purpose, voluntarily participate, and sign the informed consent form;\n\n  （5）Patients scheduled to receive flow diverter treatment;\n\n  （6）Patients willing to complete follow-up evaluations in accordance with the clinical study protocol.\n\nExclusion Criteria:\n\n* （1）Patients with two or more multiple aneurysms who require secondary treatment within one month; （2）Female patients who are planning to become pregnant, are pregnant, or are breastfeeding;\n\n  （3）Pre-onset modified Rankin Scale (mRS) score ≥ 2;\n\n  （4）Patients complicated with systemic infectious diseases (latent or active stage), ulcerative colitis, diverticulitis, liver cirrhosis, myasthenia gravis, or ocular herpes simplex; patients with contraindications to glucocorticoids, such as active peptic ulcer and severe fungal infection;\n\n  （5）Ruptured aneurysms, recurrent aneurysms, infectious aneurysms, dissecting aneurysms; complicated with arteriovenous malformation, dural arteriovenous fistula, spinal dural arteriovenous fistula, moyamoya disease, etc.;\n\n  （6）Patients with symptomatic cerebrovascular stenosis ≥ 70%;\n\n  （7）Patients who have had a stroke (cerebral hemorrhage, cerebral infarction) within the past 30 days;\n\n  （8）Patients scheduled to undergo other surgical\u002Finterventional procedures within 30 days;\n\n  （9）Patients with severe comorbidities unsuitable for anesthesia or surgical treatment, such as major diseases of the heart, lungs, liver, spleen, and kidneys, atrial fibrillation, brain tumors, severe active infections, disseminated intravascular coagulation, and severe psychiatric history;\n\n  （10）Patients who cannot receive antiplatelet aggregation or anticoagulant therapy;\n\n  （11）Hypersensitivity to methylprednisolone sodium succinate;\n\n  （12）Patients receiving long-term hormone therapy (≥ 1 week) due to other comorbidities before surgery;\n\n  （13）Patients taking hepatic enzyme-inducing drugs, such as barbiturates, rifampicin, rifabutin, carbamazepine, phenytoin, primidone, and aminoglutethimide; or patients taking hepatic enzyme-inhibiting drugs, such as erythromycin and ketoconazole;\n\n  （14）Patients undergoing chronic hemodialysis or with severe renal insufficiency (glomerular filtration rate \\\u003C 30 ml\u002Fmin or serum creatinine \\> 220 μmol\u002FL (2.5 mg\u002Fdl));\n\n  （15）Systolic blood pressure \\> 180 mmHg or diastolic blood pressure \\> 110 mmHg that is uncontrollable with oral antihypertensive drugs;\n\n  （16）Blood glucose \\\u003C 2.8 mmol\u002FL or \\> 22.2 mmol\u002FL;\n\n  （17）Patients who have received a vaccine injection within the past month or have a plan for vaccination;\n\n  （18）Patients who cannot understand or are unwilling to complete follow-up evaluations in accordance with the clinical study protocol;\n\n  （19）Patients with advanced diseases with an expected life expectancy of \\\u003C 6 months;\n\n  （20）Patients currently participating in other clinical trials.",{"count":86,"type":21},864,[54],"Study Title: Testing Methylprednisolone to Prevent Strokes After a Stent Procedure for Brain Aneurysms\n\nWhat is the purpose of this study? This study aims to find out if a short course of a steroid medicine called methylprednisolone can help prevent strokes and other brain-related complications in patients who have a \"flow diverter\" stent placed to treat an unruptured brain aneurysm. The main goal is to see if this treatment reduces the combined number of new strokes (both clot-related and bleeding-related) or brain injury-related deaths within the first 30 days after the procedure.\n\nWho can participate? Adults aged 18 or older with an unruptured brain aneurysm (size 3-25mm) who are scheduled to receive a flow-diverting stent and can provide informed consent may be eligible. Key reasons someone might not be able to join include: having multiple aneurysms needing quick treatment, being pregnant or breastfeeding, having a history of recent stroke, having active infections or stomach ulcers, having severe kidney disease, having very high\u002Funcontrolled blood pressure or blood sugar, or already being on long-term steroid therapy.\n\nWhat will happen in the study?\n\nThis is a multicenter, randomized, double-blind study. This means:\n\nParticipants will be randomly assigned (like flipping a coin) to one of two groups.\n\nOne group will receive methylprednisolone. The other group will receive a placebo (an inactive substance that looks identical).\n\nNeither the participants nor their doctors will know which treatment is being given.\n\nAll participants will receive the standard care for the stent procedure and aftercare.\n\nHow long will the study last? The treatment period is short (around the time of the procedure). Participants will be closely monitored in the hospital and will have a follow-up visit around 30 days after the procedure to check their health status.\n\nWhat will be measured? The researchers will mainly track whether participants have any stroke or brain injury-related death in the first 30 days. They will also check for other complications like bleeding, infections, and changes in daily function and quality of life. Safety will be monitored throughout.\n\nHow many people will take part? The study plans to enroll approximately 864 participants across multiple hospitals.\n\nStudy Dates:\n\nThe study is expected to start enrolling patients in January 2026 and finish in August 2027.\n\nWho is organizing the study? This study is sponsored and led by Zhujiang Hospital, Southern Medical University.",[90,25,59,91,92],"Unruptured Intracranial Aneurysms","Methylprednisolone","Flow Diverter",[66,65,91,25],"2026-01-17",{"date":96,"type":34},"2026-01-20",{"date":98,"type":21},"2026-01-30",{"date":100,"type":21},"2027-09-01",{"name":76,"class":41},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":112,"conditions":113,"keywords":116,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":77},"100541923","cognitive-decline-and-underlying-mechanisms-in-symptomatic-intracranial-artery-stenosis-patients-a-cohort-study-100541923","NCT06336174","Cognitive Decline and Underlying Mechanisms in Symptomatic Intracranial Artery Stenosis Patients: A Cohort Study","Cognitive Decline and Underlying Mechanisms in Symptomatic Intracranial Atherosclerotic Stenosis Patients: A Multicenter Cohort Study","Inclusion Criteria:\n\n* Age between 18 and 80 years\n* Severe stenosis (≥70%-99%) of atherosclerotic internal carotid artery (C6 segment, C7 segment) or middle cerebral artery (M1 segment) confirmed by digital subtraction angiography (DSA) or at least two of the following non-invasive examinations: magnetic resonance angiography (MRA), computed tomography angiography (CTA), or transcranial Doppler (TCD)\n* Transient ischemic attack (TIA) or minor stroke (National Institute of Health Stroke Scale \\[NIHSS\\] score ≤ 4 points)\n* Right-handed and able to cooperate in neuropsychological tests\n* At least 14 days post-onset of cerebral infarction or TIA\n* Signed informed consent\n\nExclusion Criteria:\n\n* Other diseases that affect cognitive function, such as cerebral hemorrhage, •Parkinson's disease, neurosyphilis, dementia, tumors, etc.\n* Right upper limb hemiplegia, aphasia, visual field defects, or visual impairments\n* More than 50% stenosis of the extracranial internal carotid artery, the vertebral artery, or the basilar artery\n* Vasculitis, moyamoya disease, and cardiogenic stroke\n* Previous history of head and neck stent implantation, carotid endarterectomy, aneurysm embolization, or other intracranial surgeries","80 Years",{"count":111,"type":21},100,"The purpose of this study is to explore the mechanism of cognitive impairment in patients with symptomatic intracranial atherosclerotic stenosis (ICAS), and further plans to explore the impact of different treatment options on cognitive function in symptomatic ICAS patients.",[114,115,25],"Intracranial Atherosclerosis","Cognitive Impairment",[117,115,118],"Symptomatic Intracranial Atherosclerosis Stenosis","Cerebravascular Event","2025-11-14",{"date":121,"type":34},"2025-11-17",{"date":123,"type":34},"2022-11-01",{"date":125,"type":21},"2026-12-31",{"name":127,"class":41},"Anhui Medical University"]